Search

Your search keyword '"Deepak, Samundeeswari"' showing total 28 results
Start Over Author "Deepak, Samundeeswari"
28 results on '"Deepak, Samundeeswari"'

2. Multi-centre national audit of juvenile localised scleroderma: describing current UK practice in disease assessment and management

Author

Lythgoe, Hanna, Almeida, Beverley, Bennett, Joshua, Bhat, Chandrika, Bilkhu, Amarpal, Brennan, Mary, Deepak, Samundeeswari, Dawson, Pamela, Eleftheriou, Despina, Harrison, Kathryn, Hawley, Daniel, Heaf, Eleanor, Leone, Valentina, Long, Ema, Maltby, Sarah, McErlane, Flora, Rafiq, Nadia, Ramanan, Athimalaipet V., Riley, Phil, Rangaraj, Satyapal, Varnier, Giulia, Wilkinson, Nick, and Pain, Clare E.

Published
2018
Full Text
View/download PDF

9. Different corticosteroid induction regimens in children and young people with juvenile idiopathic arthritis: the SIRJIA mixed-methods feasibility study

Author

Jones, Ashley P, primary, Clayton, Dannii, additional, Nkhoma, Gloria, additional, Sherratt, Frances C, additional, Peak, Matthew, additional, Stones, Simon R, additional, Roper, Louise, additional, Young, Bridget, additional, McErlane, Flora, additional, Moitt, Tracy, additional, Ramanan, Athimalaipet V, additional, Foster, Helen E, additional, Williamson, Paula R, additional, Deepak, Samundeeswari, additional, Beresford, Michael W, additional, and Baildam, Eileen M, additional

Published
2020
Full Text
View/download PDF

16. FRI0541 HIGHLY ELEVATED FERRITIN LEVELS ARE ASSOCIATED WITH HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS/MACROPHAGE ACTIVATION SYNDROME – ARE WE MISSING TREATABLE DIAGNOSES? A RETROSPECTIVE SERVICE EVALUATION OF DIAGNOSIS IN PATIENTS WITH FERRITIN >10,000 MICROGRAM/L

Author

Sen, Ethan, primary, Almeida, Beverley, additional, Moran, Louise, additional, Foley, Charlene, additional, Abdelrahman, Nagla, additional, Close, Rosie, additional, Long, Ema-Louise, additional, Bennett, Joshua, additional, Palman, Jason, additional, Anderson, Catriona, additional, Mclellan, Kirsty, additional, Deepak, Samundeeswari, additional, Gallagher, Kathy, additional, Bale, Peter, additional, Mahmood, Kamran, additional, Pain, Clare, additional, Mcerlane, Flora, additional, Ramanan, Athimalaipet, additional, and Tattersall, Rachel, additional

Published
2019
Full Text
View/download PDF

21. R06 Highly elevated ferritin levels are associated with haemophagocytic lymphohistiocytosis/macrophage activation syndrome: are we missing treatable diagnoses? A retrospective service evaluation of diagnosis in patients with ferritin >10,000 μg/L

Author

Sen, Ethan S, primary, Almeida, Beverley, additional, Moran, Louise, additional, Foley, Charlene, additional, Close, Rosie, additional, Long, Ema-Louise, additional, Bennett, Joshua, additional, Palman, Jason, additional, Anderson, Catriona M, additional, McLellan, Kirsty, additional, Deepak, Samundeeswari, additional, Gallagher, Kathy, additional, Bale, Peter, additional, Mahmood, Kamran, additional, Pain, Clare, additional, McErlane, Flora, additional, Ramanan, A V, additional, and Tattersall, Rachel S, additional

Published
2018
Full Text
View/download PDF

22. 302 Highly elevated ferritin levels are associated with haemophagocytic lymphohistiocytosis/macrophage activation syndrome: are we missing treatable diagnoses? A retrospective service evaluation of diagnosis in patients with ferritin >10,000 microgram/L

Author

Sen, Ethan S, primary, Moran, Louise, additional, Almeida, Beverley, additional, Close, Rosie, additional, Long, Ema-Louise, additional, Bennett, Joshua, additional, Anderson, Catriona M, additional, McLellan, Kirsty, additional, Deepak, Samundeeswari, additional, Gallagher, Kathy, additional, Bale, Peter, additional, Mahmood, Kamran, additional, Pain, Clare, additional, McErlane, Flora, additional, and Tattersall, Rachel S, additional

Published
2018
Full Text
View/download PDF

27. Comparing Rituximab and Cyclophosphamide in Induction Therapy for Childhood-Onset ANCA-Associated Vasculitis: An ARChiVe registry-cohort study.

Author

Gagne SJ, Sivaraman V, Bosman ES, Klamer B, Morishita KA, Huber A, Orjuela A, Eberhard B, Myrup C, Gerstbacher D, Foell D, Al-Abadi E, McErlane F, Cook K, Wagner-Weiner L, Elder M, Moorthy LN, Dancey P, Yeung R, Khubchandani R, Deepak S, Charuvanij S, Tarvin S, Shenoi S, Tanner T, Brown K, and Cabral DA

Abstract

Objective: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are chronic life-threatening vasculitides requiring substantial immunotherapy. Adult trials identified rituximab (RTX) as an alternative to cyclophosphamide (CYC) for remission-induction of GPA/MPA. Disease rarity has limited feasibility of similar trials in pediatrics. We aim to evaluate the relative efficacy and toxicity of CYC and RTX for childhood GPA/MPA through registry-based comparative evaluation., Methods: From A Registry of Childhood Vasculitis we identified GPA/MPA patients who received induction with RTX or CYC. Pediatric vasculitis activity score (PVAS) and pediatric vasculitis damage index (pVDI) evaluated disease activity and damage. Descriptive statistics summarized patient characteristics. RTX/CYC comparisons used logistic regression for primary outcomes of post-induction remission (PVAS=0) or low disease activity (PVAS<2). Hospital admission for adverse events and pVDI were compared using logistic regression and ordinal regression, respectively., Results: Among 104 patients, 43% received RTX, 46% CYC, 11% both. Treatment groups did not significantly differ for diagnosis PVAS and onset age. There was no difference in remission between groups (63% overall; OR 1.07, 95% CI: 0.45, 2.52). Hospitalizations occurred in 22% of RTX patients versus 10% on CYC (OR 2.27, 95% CI: 0.73, 7.05). The median 12-month pVDI was one in both groups (OR 0.98, 95% CI 0.43, 2.22)., Conclusion: This is the first study comparing CYC and RTX for induction in pediatric GPA/MPA. No significant differences were shown in rates of remission, severe adverse events, or organ damage. Limitations included lack of standardized treatment regimens, retrospectivity, and lack of longitudinal adverse drug-related event data., (This article is protected by copyright. All rights reserved.)

Published
2024
Full Text
View/download PDF

28. The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope.

Author

Mercer L, Abhishek A, Kavirayani A, Ahmed A, Davidson A, Foulkes A, Jones C, Nash C, Rose-Parfitt E, Dhillon E, Zabate G, Twohig H, De Vere H, Scott J, Reynolds J, Holmes J, Hartley K, Warrier K, Nowak K, Parsons K, Bechman K, Bray L, Adikari M, Wood N, Faithfull N, Gullick N, Saha P, Heaton R, Deepak S, Hider S, Khalid S, Said SS, Ryan S, Kyle S, Raghuvanshi S, Tan SY, Shivamurthy V, and Galloway J

Abstract

This guideline will provide up-to-date, evidence-based recommendations on the safe use of non-biologic DMARDs, also called conventional synthetic DMARDs (csDMARD), across the full spectrum of autoimmune rheumatic diseases. The guideline will update the guideline published in 2017 and will be expanded to include people of all ages. Updated information on the monitoring of DMARDs and vaccinations will be included. The guideline will be developed using the methods and processes described in the British Society for Rheumatology's 'Creating clinical guidelines: our protocol', updated 2023., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results